Drugs Made In America Acquisition (NASDAQ:DMAA) Announces Quarterly Earnings Results

Drugs Made In America Acquisition (NASDAQ:DMAA) released its quarterly earnings data on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, FiscalAI reports.

Drugs Made In America Acquisition Stock Performance

Drugs Made In America Acquisition stock traded down $0.01 during mid-day trading on Thursday, hitting $10.59. 102 shares of the company were exchanged, compared to its average volume of 100,374. The business has a fifty day moving average of $10.52 and a 200 day moving average of $10.43. Drugs Made In America Acquisition has a 1-year low of $10.10 and a 1-year high of $10.60.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new stake in shares of Drugs Made In America Acquisition during the third quarter worth $161,000. Sandia Investment Management LP bought a new stake in shares of Drugs Made In America Acquisition during the third quarter worth $161,000. Radcliffe Capital Management L.P. grew its holdings in shares of Drugs Made In America Acquisition by 3.5% during the fourth quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock worth $5,673,000 after purchasing an additional 18,708 shares during the last quarter. Lineage Point Capital LP bought a new stake in shares of Drugs Made In America Acquisition during the fourth quarter worth $330,000. Finally, Shaolin Capital Management LLC grew its holdings in shares of Drugs Made In America Acquisition by 50.0% during the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock worth $1,540,000 after purchasing an additional 50,000 shares during the last quarter.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.